Literature DB >> 27193133

Evidence for potential involvement of pro-inflammatory adipokines in the pathogenesis of idiopathic intracranial hypertension.

Bedia Samancı1, Yavuz Samancı2,3, Erdem Tüzün3, Güneş Altıokka-Uzun1, Esme Ekizoğlu1, Sema İçöz1, Erdi Şahin1, Cem İsmail Küçükali3, Betül Baykan1.   

Abstract

Background Although specific role players are currently unknown, contribution of inflammatory mediators has been suggested in the pathophysiology of idiopathic intracranial hypertension (IIH), which is a disease more prevalent in obese female individuals of childbearing age. We aimed to investigate the levels of adipokines and cytokines to demonstrate possible markers for inflammation that participate in IIH pathophysiology and their association with clinical features of IIH. Methods IIH patients, diagnosed according to the revised criteria, and age-, gender- and body mass index (BMI)-matched healthy controls were enrolled in this study. Serum samples were evaluated for insulin-like growth factor 1, insulin, nesfatin, adiponectin, interleukin (IL)-1β, IL-6, IL-8, leptin, plasminogen activator inhibitor type-1, resistin, tumour necrosis factor-alpha (TNF-α) and monocyte chemotactic protein 1 via enzyme-linked immunosorbent assay or multiplex immunoassays. Results IL-1β level was significantly higher ( p = 0.012), and IL-8 and TNF-α levels were significantly lower in the IIH group ( p < 0.001 and p = 0.008, respectively) compared to the control group. There were no correlations between the cytokine/adipokine levels and age, BMI, disease duration, and cerebrospinal fluid oligoclonal bands. There were also no significant differences in cytokine and adipokine levels between IIH patients regarding visual impairment. However, statistically significant differences were found between IIH patients with relapse versus healthy controls regarding IL-1β ( p = 0.007), IL-8 ( p = 0.001) and TNF-α ( p = 0.017) levels. Other investigated cytokines and adipokines showed no significant alterations in IIH patients investigated in the remission period. Conclusion Altered serum levels of IL-1β, IL-8 and TNF-α seem to be associated with IIH pathogenesis, and these cytokines may be used as prognostic markers in IIH to predict relapse.

Entities:  

Keywords:  Adipokines; cytokines; idiopathic intracranial hypertension; nesfatin; obesity

Mesh:

Substances:

Year:  2016        PMID: 27193133     DOI: 10.1177/0333102416650705

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  9 in total

1.  Glial and neuronal antibodies in patients with idiopathic intracranial hypertension.

Authors:  Güneş Altıokka-Uzun; Ece Erdağ; Betül Baykan; John Tzartos; Duygu Gezen-Ak; Bedia Samancı; Erdinç Dursun; Paraskevi Zisimopoulou; Katerina Karagiorgou; Christos Stergiou; Erdi Şahin; Esme Ekizoğlu; Murat Kürtüncü; Erdem Tüzün
Journal:  Neurol Sci       Date:  2017-07-21       Impact factor: 3.307

2.  Transverse Sinus Stenosis Is the Most Sensitive MR Imaging Correlate of Idiopathic Intracranial Hypertension.

Authors:  P P Morris; D F Black; J Port; N Campeau
Journal:  AJNR Am J Neuroradiol       Date:  2017-01-19       Impact factor: 3.825

Review 3.  Cerebral Venous Outflow Implications in Idiopathic Intracranial Hypertension-From Physiopathology to Treatment.

Authors:  Sorin Tuță
Journal:  Life (Basel)       Date:  2022-06-08

Review 4.  Perspectives on diagnosis and management of adult idiopathic intracranial hypertension.

Authors:  Irini Chatziralli; Panagiotis Theodossiadis; George Theodossiadis; Ioannis Asproudis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-04-04       Impact factor: 3.117

Review 5.  Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension.

Authors:  Zerin Alimajstorovic; Connar S J Westgate; Rigmor H Jensen; Sajedeh Eftekhari; James Mitchell; Vivek Vijay; Senali Y Seneviratne; Susan P Mollan; Alexandra J Sinclair
Journal:  Eye (Lond)       Date:  2020-01-02       Impact factor: 3.775

6.  Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension.

Authors:  Connar Sj Westgate; Hannah F Botfield; Zerin Alimajstorovic; Andreas Yiangou; Mark Walsh; Gabrielle Smith; Rishi Singhal; James L Mitchell; Olivia Grech; Keira A Markey; Daniel Hebenstreit; Daniel A Tennant; Jeremy W Tomlinson; Susan P Mollan; Christian Ludwig; Ildem Akerman; Gareth G Lavery; Alexandra J Sinclair
Journal:  JCI Insight       Date:  2021-05-24

7.  Infectious and inflammatory disorders might increase the risk of developing idiopathic intracranial hypertension - a national case-control study.

Authors:  Anna Sundholm; Sarah Burkill; Elisabet Waldenlind; Shahram Bahmanyar; A Ingela M Nilsson Remahl
Journal:  Cephalalgia       Date:  2020-05-25       Impact factor: 6.292

8.  A New Perspective on the Pathophysiology of Idiopathic Intracranial Hypertension: Role of the Glia-Neuro-Vascular Interface.

Authors:  Per Kristian Eide; Hans-Arne Hansson
Journal:  Front Mol Neurosci       Date:  2022-07-12       Impact factor: 6.261

9.  Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension.

Authors:  Connar S J Westgate; Keira Markey; James L Mitchell; Andreas Yiangou; Rishi Singhal; Paul Stewart; Jeremy W Tomlinson; Gareth G Lavery; Susan P Mollan; Alexandra J Sinclair
Journal:  Eur J Endocrinol       Date:  2022-07-04       Impact factor: 6.558

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.